Have you been diagnosed with heart failure?

Are you interested in participating in a clinical trial of a new medication for heart failure?

We are a clinical research organisation, based in London Bridge (London, UK) and are undertaking an important clinical trial of a new medication for people with heart failure. This is a study to obtain information on the safety and the way this new medication for heart failure works.

Heart failure affects approximately 900,000 people in the UK. Having heart failure means that the heart is unable to pump blood around the body properly. Heart failure usually occurs because the heart has become too weak, stiff or has been damaged, for example after a heart attack. People with heart failure commonly experience symptoms of fatigue, swelling (ankles and legs) and shortness of breath. There are treatments available to control these symptoms, but there isn’t a cure for heart failure at the moment. The information gathered during this clinical trial may support further drug development, including larger trials in patients with heart failure.

There are no expected benefits to you from participation in this study, it is purely for research purposes. By taking part in this study, you may be helping future patients by contributing to medical knowledge about heart failure.

To be eligible for this trial you need to be:

  • Aged 18 or older
  • Diagnosed with heart failure with reduced ejection fraction (reduced total amount of blood ejected from the heart)
  • Currently taking medication for heart failure treatment, with no dose changes of these medication in the past 2 weeks
  • Registered with a GP who will be informed of your participation

A list of other criteria will be applied by the study doctor to assess your eligibility for the study.

Study participation

Approximately 5 patients with heart failure will participate in this study.

You will need to attend a screening appointment within 4 weeks of dosing. If successful, you will be required to attend our unit for 3 periods of 1 day. Each period will be separated by a wash out period of up to 28 days. The day after you receive each dose and 30 days after the 3rd period, a follow-up phone call will be made to find out about your general status.

Your participation for this study will last up to 4.5 months and in recognition of your time involved in this study, you will receive an hourly rate of £7.50/hour if you qualify for participation.

Interested in participating?

Register your interest in this clinical trial

Email: volunteer@richmondpharmacology.com

Call us: weekdays between 09h00 and 17h00 on +44 (0) 207 042 5800, +44 (0) 800 0856 464 or +44 (0) 208 664 5200 (choose option 1) to speak to a member of our Volunteer Recruitment team.

Address: Richmond Pharmacology Ltd, 1A Newcomen Street, London Bridge, London, SE1 1YR

Want to know more about the study?

Hear from one of our volunteers who recently took part in the study and their experiences on the trial.

Ref: C17038_OCT 2017 (email_website_advert text)

The contents of this advert have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.

You may be required to remain resident in the unit until resolution of any safety issues, after which you will be discharged from the unit at the discretion of the study doctor.

Register for this clinical trial